Crizotinib in advanced ROS1-rearranged non-small cell lung cancer (NSCLC): updated results from PROFILE 1001

Date

09 Oct 2016

Session

NSCLC, metastatic

Presenters

Alice Shaw

Citation

Annals of Oncology (2016) 27 (6): 416-454. 10.1093/annonc/mdw383

Authors

A. Shaw1, G.J. Riley2, Y. Bang3, D. Kim4, D.R. Camidge5, M. Varella-Garcia5, A.J. Lafrate1, G. Shapiro6, M. Winter7, T. Usari8, S.C. Wang7, K. Wilner7, J.W. Clark1, S.I. Ou9

Author affiliations

  • 1 Massachusetts General Hospital Cancer Center, Massachusetts General Hospital, 02114 - Boston/US
  • 2 Memorial Sloan-kettering Cancer Center, Memorial Sloan-Kettering Cancer Center, New York/US
  • 3 Department Of Internal Medicine, Seoul National University Hospital (SNUH)-Yongon Campus, 110-744 - Seoul/KR
  • 4 Department Of Internal Medicine, Seoul National University Hospital, Seoul/KR
  • 5 Cancer Center, University of Colorado, Aurora/US
  • 6 Early Drug Development Centre, Dana-Farber Cancer Institute, Boston/US
  • 7 Oncology, Pfizer, La Jolla/US
  • 8 Oncology, Pfizer, Milano/IT
  • 9 University Of California At Irvine, University of California at Irvine, Irvine/US
More

Resources

Background

In the phase I study PROFILE 1001, crizotinib showed marked antitumor activity in advanced ROS1-rearranged NSCLC (Shaw, N Engl J Med 2014). We present updated data for 53 patients (pts) with ROS1-rearranged NSCLC from this ongoing study (NCT00585195).

Methods

ROS1 status was determined by break-apart FISH test or RT-PCR test. All pts received crizotinib at a starting dose of 250 mg orally twice daily.

Results

Fifty-three pts enrolled and were treated with crizotinib for a median treatment duration of 23.2 months. All were included in the efficacy and safety analyses. At data cutoff (November 30, 2014), treatment was ongoing in 25 pts (47%). The median age of pts was 55 years, 57% were female, and 57% and 40% were white and Asian, respectively; all were never or former smokers. The objective response rate (ORR) was 70% (95% CI: 56, 82), which included five complete responses and 32 partial responses; 11 pts had stable disease. By independent radiology review (n = 50), ORR was 66% (95% CI: 51, 79). Responses were durable (median duration of response not reached [NR]; 95% CI: 15.2, NR). ORR was consistent across baseline and disease characteristics, and appeared independent of the percentage of ROS1-rearranged cells. Median progression-free survival was 19.3 months (95% CI: 14.8, NR). At a median follow-up of 25.4 months, median overall survival was NR; the probabilities of survival at 6 and 12 months were 91% (95% CI: 79, 96) and 79% (95% CI: 65, 88), respectively. The safety profile was similar to that of crizotinib in pts with ALK-positive NSCLC. The most common treatment-related adverse events (TRAEs) were vision disorder (85%), nausea (49%), edema (45%), diarrhea (42%), and vomiting (38%), mainly grade 1 or 2 in severity. The most common grade 3 TRAEs were hypophosphatemia (13%), neutropenia (9%), and elevated transaminases (4%), and there were no grade 4 TRAEs. Of 16 deaths on study, none were attributed to crizotinib.

Conclusions

These updated data confirm the clinically meaningful benefit and safety of crizotinib in pts with advanced ROS1-rearranged NSCLC.

Clinical trial identification

Clinicaltrials.gov: NCT00585195

Legal entity responsible for the study

N/A

Funding

Pfizer

Disclosure

Y-J. Bang: Research funding from Pfizer to their institution. D.R. Camidge: Honararia from Pfizer. M. Winter, T. Usari, S.C. Wang, K. Wilner: Pfizer employee. All other authors have declared no conflicts of interest.

Resources from the same session

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings